There are rapid advancements happening regarding treatment options for patients with diffuse large B-cell lymphoma (DLBCL). The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045